Narrative review / 2019
An expert consensus recommends Ginkgo biloba extract EGb 761 for mild cognitive impairment and dementia with or without cerebrovascular disease.
The Asian Clinical Expert Group on Neurocognitive Disorders compiled evidence-based consensus recommendations on using Ginkgo biloba extract EGb 761® for neurocognitive disorders. The review reports that randomized trials and meta-analyses showed significant improvements in cognitive function, neuropsychiatric symptoms, activities of daily living, and quality of life versus placebo in mild-to-moderate dementia, as well as symptomatic improvement in mild cognitive impairment. Safety analyses indicated a positive risk-benefit profile, and trials and meta-analyses did not support an increased bleeding risk. The Expert Group foresees an important role for EGb 761® alone or as add-on therapy, aligned with local clinical guidelines.
- Study type
- Expert consensus and narrative review
- Who was studied
- Patients with dementia or mild cognitive impairment
- What was measured
- Cognitive function, neuropsychiatric symptoms, ADL, quality of life, and safety
THE PAPER
Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®.
Kandiah N, Ong PA, Yuda T, Ng LL, Mamun K, Merchant RA, Chen C, Dominguez J, Marasigan S, Ampil E, Nguyen VT, Yusoff S, Chan YF, Yong FM, Krairit O, Suthisisang C, Senanarong V, Ji Y, Thukral R, Ihl R. CNS Neurosci Ther, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.